This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (December 2020) |
Company type | Public |
---|---|
Industry | Pharmaceutical |
Founded | Merger of Pharmacia AB & The Upjohn Company |
Fate | Acquired by Pfizer |
Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. [1] Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.
In 1997, the biotechnology division of the company Pharmacia Biotech merged with Amersham Life Science with the new merged entity being known as Amersham Pharmacia Biotech. [2] [3] In 2001, the company was renamed Amersham Biotech. [4] In 2002, Pharmacia sold its share of the company to Amersham plc. [5] [6] In 2004, Amersham Biosciences was acquired by GE Healthcare. [7]
In 1998, the nutrition division of the company was sold to Fresenius. [8]
Monsanto acquired the pharmaceutical company G. D. Searle & Company in 1985. [9] In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote celecoxib, an anti-inflammatory drug used to treat arthritis. [10] [11] Branded as Celebrex, celecoxib was approved by the FDA in 1998. [12] In December 1999, Pharmacia & Upjohn merged with the American biotechnology and medical company, Monsanto and renamed itself Pharmacia. [13] The company retained Monsanto's pharmaceutical division - then known as Searle - and spun off the remaining interests as the "new Monsanto". [14] [15] The newly merged pharmaceutical entity changed its name to Pharmacia Corp. [16]
In July 2002, Pharmacia Corp. and Pfizer announced an agreement that Pfizer would purchase Pharmacia; control of celecoxib was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. [17] The deal was finalized in April 2003. [18]
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
Pharmacia Corp. Acquired by Pfizer, 2002 |
| ||||||||||||||||||||||||||||||||||||
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's
terms of use. It may require cleanup to comply with Wikipedia's
content policies, particularly
neutral point of view. (December 2020) |
Company type | Public |
---|---|
Industry | Pharmaceutical |
Founded | Merger of Pharmacia AB & The Upjohn Company |
Fate | Acquired by Pfizer |
Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. [1] Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.
In 1997, the biotechnology division of the company Pharmacia Biotech merged with Amersham Life Science with the new merged entity being known as Amersham Pharmacia Biotech. [2] [3] In 2001, the company was renamed Amersham Biotech. [4] In 2002, Pharmacia sold its share of the company to Amersham plc. [5] [6] In 2004, Amersham Biosciences was acquired by GE Healthcare. [7]
In 1998, the nutrition division of the company was sold to Fresenius. [8]
Monsanto acquired the pharmaceutical company G. D. Searle & Company in 1985. [9] In 1998, Searle and the Monsanto Pharma Sector partnered with Pfizer to develop and promote celecoxib, an anti-inflammatory drug used to treat arthritis. [10] [11] Branded as Celebrex, celecoxib was approved by the FDA in 1998. [12] In December 1999, Pharmacia & Upjohn merged with the American biotechnology and medical company, Monsanto and renamed itself Pharmacia. [13] The company retained Monsanto's pharmaceutical division - then known as Searle - and spun off the remaining interests as the "new Monsanto". [14] [15] The newly merged pharmaceutical entity changed its name to Pharmacia Corp. [16]
In July 2002, Pharmacia Corp. and Pfizer announced an agreement that Pfizer would purchase Pharmacia; control of celecoxib was often mentioned as a key reason for Pfizer's acquisition of Pharmacia. [17] The deal was finalized in April 2003. [18]
The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors:
Pharmacia Corp. Acquired by Pfizer, 2002 |
| ||||||||||||||||||||||||||||||||||||